MMV533的安全性、耐受性、药代动力学及抗疟活性:一项1a期首次人体随机递增剂量与食物效应研究及一项1b期恶性疟原虫人体感染研究
两项试验评估MMV533的安全性、耐受性、药代动力学及对血液期恶性疟原虫的活性。1a期首次人体试验中,单次口服5-160 mg的MMV533不良事件与剂量无明显关系,高脂餐后AUC0-last的几何均值比(进食:空腹)为112.0(90% CI 89.6-140.0)。1b期人体感染研究中,100 mg组log10PRR48为2.27(1.99-2.56),寄生虫清除半衰期为6.36 h(5.64-7.28)。
要点
- MMV533单次口服5-160 mg的安全性可接受,不良事件与剂量无明显关系。
- 高脂餐后MMV533 AUC0-last的几何均值比(进食:空腹)为112.0(90% CI 89.6-140.0)。
- 100 mg组log10PRR48为2.27(1.99-2.56),寄生虫清除半衰期为6.36 h(5.64-7.28)。
核心结论
- MMV533具有可接受的安全性和耐受性特征、确证的杀寄生虫活性及长半衰期,支持其作为新抗疟联合疗法组分进入疟疾患者临床试验。
研究设计与样本
- 1a期首次人体试验在澳大利亚墨尔本Nucleus Network进行,部分1为双盲、随机、安慰剂对照、序贯递增剂量研究,部分2为开放标签、随机、两周期交叉、食物效应预试验。
- 1b期开放标签人体感染研究在澳大利亚赫斯顿Nucleus Network进行,入选者为18-55岁、体重至少50 kg、BMI 18-32 kg/m2且无疟疾史的成年人。
- 部分1将六个队列(每队列最多8人)按3:1随机分配至单次口服MMV533 5、10、20、50、100、160 mg或安慰剂,随访至第28天。
- 部分2将30 mg MMV533开放标签给予9人,按1:1简单随机分配至空腹-进食组(n=4)或进食-空腹组(n=5),经21天洗脱期后交叉,随访至第42天。
- 人体感染研究将7人按1:1:1简单随机分配至20 mg(n=3)、35 mg(n=2)、100 mg(n=2)三个剂量组,随访至第28天。
主要发现
- 部分1中,MMV533给药后38名参与者中24名(63%)发生不良事件,与剂量无明显关系,安慰剂组12名中6名(50%)发生不良事件。
- 部分1中,MMV533组4名(11%)报告治疗相关不良事件,安慰剂组1名(8%)报告,与剂量无关。
- 部分2中,空腹状态8名参与者中3名(38%)报告不良事件,进食状态9名中4名(44%)报告,食物无明显影响。
- MMV533达峰时间为4.0-6.0 h,表观半衰期为103.8-127.2 h。
- 人体感染研究中,MMV533 100 mg组log10PRR48为2.27(1.99-2.56),PCT1/2为6.36 h(5.64-7.28),lag phase为2 h。
关键数值与推荐
- 1a期主要结局为安全人群中治疗期出现的不良事件及其与MMV533的关系。
- 1b期主要结局为药效学人群中48小时寄生虫减少率(log10PRR48)、寄生虫清除半衰期(PCT1/2)和lag phase。
- 两项研究中MMV533药代动力学均为次要结局,在药代动力学人群中评估。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel antimalarials are needed to address emerging resistance to artemisinin and partner drugs. We did two trials to evaluate safety, tolerability, pharmacokinetics, and activity against blood stage Plasmodium falciparum for the drug candidate MMV533. METHODS: A phase 1a first-in-human (FIH) trial was conducted at Nucleus Network (Melbourne, VIC, Australia). Part 1 was a double-blind, randomised, placebo-controlled, sequential ascending dose study and part 2 was an open-label, randomised, two-period crossover, pilot food effect study. A phase 1b, open-label, volunteer infection study (VIS) was conducted at Nucleus Network (Herston, QLD, Australia). Eligible participants were adults aged 18-55 years, with a bodyweight of at least 50 kg and BMI of 18-32 kg/m2 and participants in the VIS were malaria-naive. In part 1 of the FIH study, six cohorts of up to eight participants were randomly assigned (3:1) to a single oral MMV533 dose (5, 10, 20, 50, 100, and 160 mg) or placebo using an automated system, with study staff and participants masked to treatment allocation, and follow-up until day 28. In part 2, MMV533 30 mg was administered open-label to one cohort of nine participants assigned by simple randomisation (1:1) to the fasted-fed (n=4) or fed-fasted (n=5) groups. After a 21-day washout period, fed and fasted groups crossed over with follow-up until day 42. In the VIS, seven participants were assigned using simple randomisation (1:1:1) to three dosing groups of 20 mg (n=3), 35 mg (n=2), or 100 mg (n=2) after parasitaemia was detected, with follow-up until day 28. The primary outcomes were treatment emergent adverse events and relationship to MMV533 for the FIH study assessed in the safety population, and in the VIS primary outcomes were parasite reduction ratio over 48 h (log10PRR48), parasite clearance half-life (PCT1/2), and lag phase assessed in the pharmacodynamic population. MMV533 pharmacokinetics was a secondary outcome for both studies, evaluated in the pharmacokinetic population. The studies are registered with ClinicalTrials.gov, NCT04323306 and NCT05205941 (completed). FINDINGS: The FIH study was conducted between July 31, 2020, and Sept 27, 2022, and the VIS between March 31 and Aug 9, 2022. 335 adults were assessed for eligibility, 71 enrolled, and 69 randomly assigned (53 in part 1 and nine in part 2 of the FIH study, and seven in the VIS). 32 (45%) of 71 participants were female and 39 (55%) were male. In part 1, 24 (63%) of 38 participants had an adverse event after MMV533 administration with no apparent relationship to dose versus six (50%) of 12 after placebo. Treatment-related adverse events were reported for four (11%) participants receiving MMV533 and one (8%) receiving placebo, with no relationship to dose. In part 2, adverse events were reported for three (38%) of eight participants when fasted and four (44%) of nine when fed, with no apparent influence of food. Time to maximum plasma concentration was 4·0-6·0 h, and apparent half-life was 103·8-127·2 h. After a high-fat meal, the geometric mean ratio (fed:fasted) of MMV533 AUC0-last was 112·0 (90% CI 89·6-140·0). In the VIS for MMV533 100 mg, log10PRR48 was 2·27 (1·99-2·56), PCT1/2 was 6·36 h (5·64-7·28), and lag phase was 2 h. INTERPRETATION: An acceptable safety and tolerability profile, confirmed parasiticidal activity, and a long half-life support progression of MMV533 into clinical trials in patients with malaria as a component of new antimalarial combination therapies. FUNDING: MMV Medicines for Malaria Venture and Bill & Melinda Gates Foundation.
引用
- Bestgen B, Jones S, Thathy V, et al. Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study. Lancet Infect Dis. 2024. PMID: 39708824. doi:10.1016/S1473-3099(24)00664-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。